Understanding GLM6: A G Protein-Coupled Receptor Involved in Neurotransmission

Target Name: GRM6

NCBI ID: G2916

GRM6

Understanding GLM6: A G Protein-Coupled Receptor Involved in Neurotransmission

Glutamate receptors are a family of transmembrane proteins that play a crucial role in cellular signaling. Metabotropic 6 (GRM6) is a G protein-coupled receptor that is expressed in various tissues and cells, including the central nervous system (CNS), and is involved in neurotransmitter signaling. Despite its importance, GRM6 has not yet been fully understood, and there are limited research studies available on its role in disease. In this article, we will review the current understanding of GRM6 and its potential as a drug target or biomarker.

Chemical Characterization

GRM6 is a 7-transmembrane protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain ( figure 1). It has a molecular weight of approximately 110 kDa and a calculated pI of 6.9 ( figure 2). GRM6 is a G protein-coupled receptor that uses a Glu-295 residue as a ligand for binding (figure 3).

GRM6 is expressed in various tissues and cells, including the CNS, and its function is involved in neurotransmitter signaling ( figure 4). It is involved in the regulation of glutamatergic neurotransmission, which is a critical aspect of neurotransmission in the CNS ( figure 5).

Disease Relevance

GRM6 has not yet been fully studied in the context of disease, and there are limited research studies available on its role in disease. However, some studies have suggested that GRM6 may be involved in various neurological disorders, including depression, anxiety, and neurodegenerative diseases (figure 6).

One potential mechanism by which GRM6 may be involved in disease is by modulating neurotransmitter release and activity. For example, some studies have suggested that GRM6 may play a role in the regulation of glutamatergic neurotransmission in the hippocampus, and that it may be involved in the development of neurodegenerative diseases (figure 7).

Drug Target Potential

GRM6 is a potential drug target due to its involvement in neurotransmission and its potential role in the regulation of various psychiatric and neurological disorders. Several studies have suggested that inhibiting GRM6 activity may be a useful strategy for treating psychiatric and neurological disorders. For example, some studies have shown that inhibiting GRM6 activity can alleviate symptoms of depression and anxiety in animal models (figure 8).

In addition, several small molecules have been shown to be potent inhibitors of GRM6 activity, and several clinical trials are underway to evaluate their potential utility as treatments for psychiatric and neurological disorders (figure 9).

Conclusion

In conclusion, GRM6 is a G protein-coupled receptor that is involved in neurotransmission and may be a drug target or biomarker for various psychiatric and neurological disorders. Further research is needed to fully understand its role in disease and to develop effective treatments based on its potential.

Protein Name: Glutamate Metabotropic Receptor 6

Functions: G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity (By similarity). Signaling stimulates TRPM1 channel activity and Ca(2+) uptake. Required for normal vision

The "GRM6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GRM6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets